Core Viewpoint - Eli Lilly plans to invest $3 billion over the next decade to expand supply chain capacity in China and build production capacity for type-2 diabetes and obesity treatment orforglipron [1] Group 1: Investment Plans - The company is committing $3 billion for the expansion of its supply chain in China [1] - The investment will focus on increasing production capacity specifically for orforglipron, a treatment for type-2 diabetes and obesity [1] Group 2: Strategic Importance - This move highlights the company's strategy to enhance its operational capabilities in a key market [1] - The investment reflects a growing emphasis on addressing diabetes and obesity, which are significant health concerns globally [1]

Time for the final trade. Tim Seymour. >> What if guy's beauty consultant knows he's got a leaky fountain.Um anyway, I know that K web and investment in Chinat is beautiful and I would stay along that trade. >> Karen, yes. In the regional bank space, Pinnacle Financial Partners.And I do like this novice merger. >> Dan. >> Yeah.Like Tim, I think you stick with the B in guy's tube. That would be Baba. Guy looks like he wants to what.>> Party. And it's the A in carved. Come on.>> Obviously. Yes. >> A few thing ...